公开(公告)号：US08921368B2

公开(公告)日：2014-12-30

申请号：US14005570

申请日：2012-03-16

Applicant: Stephen T. Wrobleski ,  Gregory D. Brown ,  Lidia M. Doweyko ,  Jingwu Duan ,  Junqing Guo ,  John Hynes ,  Bin Jiang ,  James Kempson ,  Shuqun Lin ,  Zhonghui Lu ,  Steven H. Spergel ,  John S. Tokarski ,  Hong Wu ,  Bingwei Vera Yang

Inventor： Stephen T. Wrobleski ,  Gregory D. Brown ,  Lidia M. Doweyko ,  Jingwu Duan ,  Junqing Guo ,  John Hynes ,  Bin Jiang ,  James Kempson ,  Shuqun Lin ,  Zhonghui Lu ,  Steven H. Spergel ,  John S. Tokarski ,  Hong Wu ,  Bingwei Vera Yang

IPC: C07D487/04 ,  C07D471/04 ,  A01N43/58 ,  A61K31/50

CPC classification number: C07D487/04 ,  C07D471/04 ,  C07D519/00

Abstract: Disclosed are compounds of Formula (I), and pharmaceutically acceptable salts thereof. The compounds of formula (I) inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases.

Abstract translation: 公开了式（I）的化合物及其药学上可接受的盐。 式（I）化合物抑制JAK3的酪氨酸激酶活性，从而使其可用于治疗炎性和自身免疫性疾病。

公开(公告)号：US20140067943A1

公开(公告)日：2014-03-06

申请号：US13606000

申请日：2012-09-06

Applicant: Todd Christopher Jackson ,  William Russell Maschmeyer ,  Bin Jiang ,  Kenneth M. Lau ,  Michael Novati

Inventor： Todd Christopher Jackson ,  William Russell Maschmeyer ,  Bin Jiang ,  Kenneth M. Lau ,  Michael Novati

IPC: G06F15/16

CPC classification number: G06Q50/01 ,  G06Q30/0269 ,  G06Q30/0631

Abstract: Based on information associated with users, a social networking system recommends one or more groups for a target user to join or to create. Characteristics of the target user, characteristics of users connected to the target user, characteristics of candidate groups in the social networking system may be used to identify groups for recommendation. The social networking system may provide questions to the target user and recommend a group to the target user based on received answers to the questions. For example, the answers to the provided question identify one or more characteristics of the target user, which are used to select a group for recommendation. Additionally, the social networking system may recommend additional users for the target user to add or invite to a group based on characteristics of the target user, the additional users, and/or the group.

Abstract translation: 基于与用户相关的信息，社交网络系统建议一个或多个组为目标用户加入或创建。 目标用户的特征，连接到目标用户的用户的特征，社交网络系统中的候选组的特征可以用于识别用于推荐的组。 社交网络系统可以向目标用户提供问题，并且基于接收到的问题答案向目标用户推荐组。 例如，提供的问题的答案识别目标用户的一个或多个特征，其用于选择用于推荐的组。 此外，社交网络系统可以基于目标用户，附加用户和/或组的特征来推荐目标用户的附加用户添加或邀请给组。

公开(公告)号：US20140065226A1

公开(公告)日：2014-03-06

申请号：US13261732

申请日：2012-03-05

Applicant: Eric Brey ,  Jennifer J. Kang-Mieler ,  Victor Perez-Luna ,  Bin Jiang ,  Pawel Drapala ,  Rolf Schäfer ,  Hans Hitz

Inventor： Eric Brey ,  Jennifer J. Kang-Mieler ,  Victor Perez-Luna ,  Bin Jiang ,  Pawel Drapala ,  Rolf Schäfer ,  Hans Hitz

IPC: A61K47/32 ,  A61K31/573

CPC classification number: A61K47/32 ,  A61K9/0014 ,  A61K9/0048 ,  A61K9/06 ,  A61K9/5153 ,  A61K31/573 ,  A61K47/34

Abstract: A thermo-responsive hydrogel, including a biocompatible monomer and/or polymer having a side chain-linked amino acid. The hydrogel is thermo-responsive at a physiological temperature, and can include, incorporate, or encapsulate a treatment agent, such as a drug composition, a biomolecule, and/or a nano-particle. The hydrogel is useful in delivering the treatment agent. The hydrogel is in a first physicochemical state for administration to a mammal. The hydrogel is thermo-responsive at a physiological temperature of the mammal, and changes to a second physicochemical state that is more solid than the first physicochemical state. In the second physicochemical state the thermo-responsive hydrogel releases the treatment agent.

Abstract translation: 一种热响应性水凝胶，包括具有侧链连接的氨基酸的生物相容性单体和/或聚合物。 水凝胶在生理温度下是热响应的，并且可以包括，掺入或包封处理剂，例如药物组合物，生物分子和/或纳米颗粒。 水凝胶可用于递送处理剂。 水凝胶处于哺乳动物的第一物理化学状态。 水凝胶在哺乳动物的生理温度下是热应答的，并且变成比第一物理化学状态更固体的第二物理化学状态。 在第二个物理化学状态下，热响应性水凝胶释放处理剂。

公开(公告)号：US08324401B2

公开(公告)日：2012-12-04

申请号：US12542762

申请日：2009-08-18

Applicant: Jingwu Duan ,  Bin Jiang

Inventor： Jingwu Duan ,  Bin Jiang

IPC: A61K31/4164 ,  A61K31/426 ,  C07D233/54

CPC classification number: C07D285/135 ,  C07D233/76 ,  C07D249/12 ,  C07D277/46 ,  C07D285/08

Abstract: Novel non-steroidal compounds are provided that are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases having the structure of formula (I): or enantiomers, diastereomers, or a pharmaceutically-acceptable salt, or hydrate, thereof, where X is A1QA2-; Q is a bond, —C(═O)—, —OC(O)—, —C(═O)NR5—, —SOp—, —SOpNR5—, —C(O)O—, —NR5C(O)—, —OC(O)NR5—, —NR5C(O)O—, —S(O)pNR5C(O)—, —C(O)NR5S(O)p— —NR5S(O)p—, or —NR5C(═O)NR6—. Y is selected from hydrogen, C1-6alkyl, OR16, substituted C1-6alkyl, cycloalkyl, aryl, heterocyclo and heteroaryl. A1 and A2 are independently selected from a bond, C1-3alkylene, or C1-3alkenylene, and R1-R11 are defined herein. Also provided are pharmaceutical compositions, combinations, and methods of treating obesity, diabetes and inflammatory- or immune-associated diseases comprising said compounds.

Abstract translation: 提供新的非甾体化合物，其可用于治疗与糖皮质激素受体，AP-1和/或NF-κB活性相关的疾病，所述疾病包括具有式（I）结构的肥胖症，糖尿病，炎症和免疫疾病 ）：或其对映异构体，非对映体或其药学上可接受的盐或水合物，其中X为AlQA2-; Q是键，-C（= O） - ， - OC（O） - ， - C（= O）NR5-，-SOp-，-SOpNR5-，-C（O） - （O）NR 5 - ， - NR 5 C（O）O-，-S（O）pNR 5 C（O） - ， - C（O）NR 5 S（O） NR5C（= O）NR6-。 Y选自氢，C 1-6烷基，OR 16，取代的C 1-6烷基，环烷基，芳基，杂环和杂芳基。 A1和A2独立地选自键，C1-3亚烷基或C1-3亚烯基，R1-R11在本文中定义。 还提供了治疗包含所述化合物的肥胖症，糖尿病和炎性或免疫相关疾病的药物组合物，组合和方法。

公开(公告)号：US08018751B1

公开(公告)日：2011-09-13

申请号：US12504523

申请日：2009-07-16

Applicant: Dinesh Maheshwari ,  Andrew Wright ,  Bin Jiang ,  Bartosz Banachowicz

Inventor： Dinesh Maheshwari ,  Andrew Wright ,  Bin Jiang ,  Bartosz Banachowicz

IPC: G11C15/00

CPC classification number: G11C15/04

Abstract: A ternary content addressable memory (TCAM) cell circuit formed in a TCAM memory cell array having cells arranged in rows and columns can include a first storage circuit with first and second data path, a second storage circuit with a third and fourth data path, and a compare circuit. No more than four conductive lines in a column wise direction have a direct electrical connection to the TCAM cell. Such conductive lines can include a first bit line coupled to the first data path and the third data path and a second bit line coupled to the second data path and the fourth data path.

Abstract translation: 形成在具有排列成行和列的单元的TCAM存储单元阵列中的三元内容可寻址存储器（TCAM）单元电路可以包括具有第一和第二数据路径的第一存储电路，具有第三和第四数据路径的第二存储电路，以及 比较电路。 在列方向上不超过四条导线与TCAM电池有直接电连接。 这样的导线可以包括耦合到第一数据路径和第三数据路径的第一位线和耦合到第二数据路径和第四数据路径的第二位线。

公开(公告)号：USD635136S1

公开(公告)日：2011-03-29

申请号：US29352726

申请日：2009-12-23

Applicant: Bin Jiang ,  Te-Hua Lee

Designer： Bin Jiang ,  Te-Hua Lee

公开(公告)号：US07625921B2

公开(公告)日：2009-12-01

申请号：US11034822

申请日：2005-01-13

Applicant: Jingwu Duan ,  James Sheppeck ,  Bin Jiang ,  John L. Gilmore

Inventor： Jingwu Duan ,  James Sheppeck ,  Bin Jiang ,  John L. Gilmore

IPC: A61K31/4748 ,  C07D401/14 ,  C07D417/12

CPC classification number: C07D471/08 ,  C07D401/12 ,  C07D401/14 ,  C07D417/12 ,  C07D417/14

Abstract: A class of novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) its stereoisomers thereof, or a solvate thereof, or a prodrug thereof, or a pharmaceutically acceptable salt thereof, where Z is CONR1R2 or CH2NR1R2 and where at least one of X1-X8 is N, and R, Ra, Rb, Rc and Rd are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.

Abstract translation: 提供了一类新型非甾体化合物，其可用于治疗与糖皮质激素受体，AP-1和/或NF-κB活性的调节相关的疾病，包括肥胖症，糖尿病，炎症和免疫疾病，并且具有 式（I）其立体异构体，或其溶剂合物或其前药，或其药学上可接受的盐，其中Z为CONR1R2或CH2NR1R2，并且其中X1-X8中的至少一个为N，R，Ra，Rb， Rc和Rd在本文中定义。 还提供了治疗肥胖症，糖尿病和包含所述化合物的炎性或免疫相关疾病的药物组合物和方法。

公开(公告)号：US07592461B2

公开(公告)日：2009-09-22

申请号：US11642508

申请日：2006-12-20

Applicant: Jingwu Duan ,  Bin Jiang

Inventor： Jingwu Duan ,  Bin Jiang

IPC: A61K31/426 ,  A61K31/433 ,  C07D277/46 ,  C07D285/135

CPC classification number: C07D285/135 ,  C07D233/76 ,  C07D249/12 ,  C07D277/46 ,  C07D285/08

Abstract: Novel non-steroidal compounds are provided that are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases having the structure of formula (I): or enantiomers, diastereomers, or a pharmaceutically-acceptable salt, or hydrate, thereof, where X is -A1QA2-; Q is a bond, —C(═O)—, —OC(O)—, —C(═O)NR5—, —SOp—, —SOpNR5—, —C(O)O—, —NR5C(O)—, —OC(O)NR5—, —NR5C(O)O—, —S(O)pNR5C(O)—, —C(O)NR5S(O)p— —NR5S(O)p—, or —NR5C(═O)NR6—. Y is selected from hydrogen, C1-6alkyl, OR16, substituted C1-6alkyl, cycloalkyl, aryl, heterocyclo and heteroaryl. A1 and A2 are independently selected from a bond, C1-3alkylene, or C1-3alkenylene, and R1-R11 are defined herein. Also provided are pharmaceutical compositions, combinations, and methods of treating obesity, diabetes and inflammatory- or immune-associated diseases comprising said compounds.

Abstract translation: 提供了新型非甾体化合物，其可用于治疗与调节糖皮质激素受体，AP-1和/或NF-κB活性相关的疾病，包括具有式（I）结构的肥胖症，糖尿病，炎症和免疫疾病： 或对映异构体，非对映异构体或其药学上可接受的盐或水合物，其中X为-A1QA2-; Q是键，-C（-O） - ， - OC（O） - ， - C（-O）NR5-，-SOp-，-SOpNR5-，-C（O） - （O）NR 5 - ， - NR 5 C（O）O-，-S（O）p NR 15 C（O） - ， - C（O）NR 5 S（O）p - ， - -NR 5 C（-O）NR 6 - 。 Y选自氢，C 1-6烷基，OR 16，取代的C 1-6烷基，环烷基，芳基，杂环和杂芳基。 A1和A2独立地选自键，C1-3亚烷基或C1-3亚烯基，R1-R11在本文中定义。 还提供了治疗包含所述化合物的肥胖症，糖尿病和炎性或免疫相关疾病的药物组合物，组合和方法。

公开(公告)号：US07579873B1

公开(公告)日：2009-08-25

申请号：US11985706

申请日：2007-11-16

Applicant: Bin Jiang ,  Sang Kong Chan

Inventor： Bin Jiang ,  Sang Kong Chan

IPC: H03K19/0175 ,  H03K3/00

CPC classification number: H03K5/01 ,  H03K5/06

Abstract: An interface driver circuit comprises N cascaded delay cells, each including a data bit input, a delayed data bit output that communicates with the data bit input of an adjacent one of the N cascaded delay cells, and a delay time input that sets delay values between receiving data at the data bit input and generating the delayed data bit output. N predrivers receive an output enable signal that is independent of the data, receive a corresponding one of the N delayed data bit outputs and generate a predriver output signal based on the output enable signal and the corresponding one of the N delayed data bit outputs.

Abstract translation: 一个接口驱动电路包括N个级联延迟单元，每个包括数据位输入，与N个级联延迟单元相邻的数据位输入通信的延迟数据位输出，以及延迟时间输入， 在数据位输入端接收数据并产生延迟的数据位输出。 N个预取器接收独立于数据的输出使能信号，接收N个延迟的数据位输出中的相应一个，并且基于输出使能信号和N个延迟的数据位输出中的相应一个产生预驱动输出信号。

公开(公告)号：US07569689B2

公开(公告)日：2009-08-04

申请号：US11034652

申请日：2005-01-13

Applicant: Jingwu Duan ,  Bin Jiang ,  James Sheppeck ,  John L. Gilmore

Inventor： Jingwu Duan ,  Bin Jiang ,  James Sheppeck ,  John L. Gilmore

IPC: A61K31/498 ,  C07D417/14

CPC classification number: C07D403/12 ,  C07D241/36 ,  C07D417/12 ,  C07D417/14

Abstract: A class of novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases, and have the structure of formula (I) its stereoisomers thereof, or a solvate thereof, or a prodrug thereof, or a pharmaceutically acceptable salt thereof, where Z is CONR1R2 or CH2NR1R2 and where at least two of X1-X4 and/or X5-X8 is N or NR18, and R, Ra, Rb, Rc, Rd, R1, R2 and R18 are defined herein. Also provided are pharmaceutical compositions and methods of treating obesity, diabetes and inflammatory or immune associated diseases comprising said compounds.

Abstract translation: 提供了一类新型非甾体化合物，其可用于治疗与糖皮质激素受体，AP-1和/或NF-κB活性的调节相关的疾病，包括肥胖症，糖尿病，炎症和免疫疾病，并且具有 式（I）其立体异构体，或其溶剂合物，或其前药，或其药学上可接受的盐，其中Z为CONR1R2或CH2NR1R2，并且其中X1-X4和/或X5-X8中的至少两个为N或NR18 ，R，R a，R b，R c，R d，R 1，R 2和R 18如本文所定义。 还提供了治疗肥胖症，糖尿病和包含所述化合物的炎性或免疫相关疾病的药物组合物和方法。